CooperCompanies will report Q4 and full year 2025 financial results on December 4, 2025, followed by a conference call.
Quiver AI Summary
CooperCompanies, a prominent medical device firm based in San Ramon, California, announced that it will release its financial results for the fourth quarter and the full year of 2025 on December 4, 2025, at 4:15 PM ET. Following this announcement, the company will conduct a conference call at 5:00 PM ET to discuss the results and any significant corporate updates. Investors can join the call using the provided dial-in number and conference ID, or by accessing an audio webcast on their investor relations website. CooperCompanies operates through its units, CooperVision, a leader in contact lenses, and CooperSurgical, which focuses on women's health and fertility, aiming to improve the lives of over fifty million individuals annually.
Potential Positives
- CooperCompanies is set to report its fourth quarter and full year 2025 financial results, indicating a commitment to transparency and communication with stakeholders.
- The scheduled conference call following the financial results release demonstrates the company's proactive approach to engaging with investors and analysts regarding its performance and developments.
- The company's strong market position as a leading medical device company, particularly in contact lenses and women’s healthcare, highlights its significance in the healthcare industry.
- CooperCompanies positively impacts over fifty million lives each year, showcasing its commitment to improving health outcomes and the well-being of individuals globally.
Potential Negatives
- None
FAQ
What date will CooperCompanies report its 2025 financial results?
CooperCompanies will report its fourth quarter and full year 2025 financial results on December 4, 2025.
What time is the conference call for discussing the financial results?
The conference call will start at 5:00 PM ET on December 4, 2025.
How can I access the audio webcast of the conference call?
The audio webcast and replay can be accessed at http://investor.coopercos.com.
Who should I contact for investor relations inquiries?
For investor relations inquiries, contact Kim Duncan at 925-460-3663 or via email at [email protected].
What are the main business units of CooperCompanies?
CooperCompanies operates through two main business units: CooperVision and CooperSurgical.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$COO Congressional Stock Trading
Members of Congress have traded $COO stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $COO stock by members of Congress over the last 6 months:
- REPRESENTATIVE ROBERT BRESNAHAN sold up to $15,000 on 05/15.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$COO Insider Trading Activity
$COO insiders have traded $COO stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $COO stock by insiders over the last 6 months:
- ALBERT G III WHITE (President & CEO) purchased 10,000 shares for an estimated $683,900
- DANIEL G MCBRIDE (EVP & Chief Operating Officer) purchased 3,000 shares for an estimated $195,120
- LAWRENCE ERIK KURZIUS purchased 2,000 shares for an estimated $136,780
- GERARD H III WARNER (President, CooperVision, Inc.) purchased 1,450 shares for an estimated $100,383
- BRIAN G ANDREWS (EVP, CFO & Treasurer) purchased 1,525 shares for an estimated $100,162
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$COO Hedge Fund Activity
We have seen 305 institutional investors add shares of $COO stock to their portfolio, and 344 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VERITAS ASSET MANAGEMENT LLP removed 3,847,698 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $273,802,189
- SUSTAINABLE GROWTH ADVISERS, LP added 3,385,059 shares (+inf%) to their portfolio in Q2 2025, for an estimated $240,880,798
- GENERATION INVESTMENT MANAGEMENT LLP removed 2,873,376 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $204,469,436
- PRICE T ROWE ASSOCIATES INC /MD/ added 2,592,441 shares (+65.6%) to their portfolio in Q2 2025, for an estimated $184,478,101
- JPMORGAN CHASE & CO removed 2,481,717 shares (-47.9%) from their portfolio in Q2 2025, for an estimated $176,598,981
- NORGES BANK removed 1,877,646 shares (-79.2%) from their portfolio in Q2 2025, for an estimated $133,613,289
- AMERIPRISE FINANCIAL INC added 1,683,561 shares (+98.8%) to their portfolio in Q2 2025, for an estimated $119,802,200
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$COO Analyst Ratings
Wall Street analysts have issued reports on $COO in the last several months. We have seen 7 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 10/13/2025
- Goldman Sachs issued a "Sell" rating on 10/01/2025
- Stifel issued a "Buy" rating on 08/28/2025
- Piper Sandler issued a "Overweight" rating on 08/28/2025
- Wells Fargo issued a "Overweight" rating on 08/28/2025
- Baird issued a "Outperform" rating on 08/28/2025
- Needham issued a "Buy" rating on 08/28/2025
To track analyst ratings and price targets for $COO, check out Quiver Quantitative's $COO forecast page.
$COO Price Targets
Multiple analysts have issued price targets for $COO recently. We have seen 11 analysts offer price targets for $COO in the last 6 months, with a median target of $83.0.
Here are some recent targets:
- Matt Miksic from Barclays set a target price of $85.0 on 10/13/2025
- David Roman from Goldman Sachs set a target price of $64.0 on 10/01/2025
- Robbie Marcus from JP Morgan set a target price of $66.0 on 08/28/2025
- David Saxon from Needham set a target price of $94.0 on 08/28/2025
- Jonathan Block from Stifel set a target price of $85.0 on 08/28/2025
- Joanne Wuensch from Citigroup set a target price of $72.0 on 08/28/2025
- Patrick Wood from Morgan Stanley set a target price of $76.0 on 08/28/2025
Full Release
SAN RAMON, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, announced today it will report fourth quarter and full year 2025 financial results on Thursday, December 4, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments.
The dial-in number for the call is 800-715-9871 and the conference ID is 2700541. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com .
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 16,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit
www.coopercos.com
.
Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
[email protected]
